US FDA’s Human Drugs Program Suffers In Adjustment Of Agency Priorities
President Trump's budget request would boost compounding and vaccines by $5m, but human drugs program would lose $4.8m in training funds.
You may also be interested in...
Number one ask is for congressional pressure to centralize rare disease expertise at the agency, but advocates also are preparing legislation that would mandate the new center.
Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.
CDER-based program lead by Marta Sokolowska will also handle benzodiazepine and stimulants activities and consult on relevant application assessments.